drugset / Trial / NCT00580320
Safety Study of Dacarbazine and Bortezomib in Melanoma and Soft Tissue Sarcoma
NaSingle-groupOpen-labelTreatment
Summary
Bortezomib will enhance the activity of dacarbazine against melanoma and soft tissue sarcoma. Weekly administration of the combination will prove to be feasible and tolerable at an appropriate dose.
Timeline
- Start
- 2004-09
- Primary completion
- 2009-10
- Completion
- 2013-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bortezomib | Small molecule | 1 mg/m2 | — |
| Subject | Bortezomib | Small molecule | 1.3 mg/m2 | — |
| Subject | Bortezomib | Small molecule | 1.6 mg/m2 | — |
| Subject | Dacarbazine | Small molecule | 190 mg/m2 | — |
| Subject | Dacarbazine | Small molecule | 250 mg/m2 | — |
| Subject | Dacarbazine | Small molecule | 330 mg/m2 | — |
| Subject | Dacarbazine | Small molecule | 440 mg/m2 | — |
| Subject | Dacarbazine | Small molecule | 580 mg/m2 | — |